OCUL OCULAR THERAPEUTIX, INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1393434 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-9.7%
TTM net income YoY-30.9%
TTM EPS YoY-0.7%
Revenue 3-yr CAGR-4.4%
Net income 3-yr CAGR—
Margins
Gross margin87.3%
Operating margin-680.9%
Net margin-648.6%
FCF margin-530.0%
EBITDA margin-667.4%
Returns
ROE-93.5%
ROA-64.3%
ROIC (approx.)—
Asset turnover0.10x
Leverage & solvency
Liabilities / assets27.2%
Debt / equity0.00x
Current ratio9.12x
Interest coverage-30.59x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue27.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.87M | $13.47M | $10.79M | $13.25M | $14.54M | $13.46M | $10.70M | $17.08M |
| Cost of revenue | $1.46M | $2.01M | $1.33M | $1.59M | $1.77M | $1.94M | $1.26M | $1.23M |
| Gross profit | $11.42M | $11.46M | $9.46M | $11.66M | $12.77M | $11.52M | $9.44M | $15.85M |
| R&D expense | $74.79M | $54.14M | $66.21M | $50.80M | $52.36M | $51.08M | $42.86M | $40.99M |
| SG&A expense | $18.83M | $22.16M | $20.01M | $17.66M | $16.02M | $14.35M | $16.35M | $14.60M |
| Operating income | -$97.86M | -$82.11M | -$93.34M | -$69.76M | -$68.70M | -$67.64M | -$63.92M | -$50.58M |
| Interest expense | $2.81M | $2.79M | $2.78M | $2.83M | $3.00M | $3.02M | $2.98M | $3.11M |
| Net income | -$94.78M | -$78.76M | -$88.61M | -$64.65M | -$69.42M | -$67.81M | -$64.05M | -$48.39M |
| EBITDA | -$95.43M | -$80.26M | -$92.06M | -$68.51M | -$67.63M | -$66.61M | -$62.94M | -$49.62M |
| EPS (basic) | -0.42 | -0.35 | -0.40 | — | -0.38 | -0.39 | -0.38 | — |
| EPS (diluted) | -0.42 | -0.35 | -0.40 | — | -0.38 | -0.39 | -0.38 | — |
| Weighted avg. shares (diluted) | 225.52M | 224.95M | 224.10M | — | 183.92M | 172.59M | 169.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $530.61M | $598.64M | $666.70M | $737.06M | $344.77M | $391.13M | $349.68M | $393.72M |
| Receivables | $31.39M | $30.26M | $24.35M | $30.65M | $30.77M | $30.41M | $25.22M | $32.39M |
| Inventory | $4.26M | $3.83M | $3.74M | $3.56M | $3.49M | $3.04M | $3.27M | $3.04M |
| Current assets | $574.60M | $644.43M | $706.00M | $782.13M | $386.98M | $433.38M | $387.69M | $440.99M |
| PP&E, net | $20.28M | $19.46M | $18.43M | $19.68M | $16.95M | $10.46M | $10.78M | $9.39M |
| Total assets | $605.65M | $671.32M | $732.53M | $808.06M | $410.88M | $451.33M | $405.92M | $457.94M |
| Current liabilities | $63.02M | $49.17M | $47.68M | $50.81M | $49.29M | $42.93M | $37.93M | $41.35M |
| Total liabilities | $164.70M | $151.28M | $150.96M | $153.75M | $152.65M | $145.42M | $139.99M | $142.59M |
| Shareholders' equity | $440.95M | $520.04M | $581.57M | $654.31M | $258.23M | $305.92M | $265.93M | $315.34M |
| Shares outstanding | 219.88M | 219.59M | 218.90M | 215.93M | 174.95M | 172.93M | 159.26M | 157.75M |
| Cash flow statement | ||||||||
| Operating cash flow | -$65.62M | -$67.27M | -$65.99M | -$54.25M | -$50.73M | -$55.24M | -$44.67M | -$39.43M |
| Capital expenditure | $3.03M | $3.37M | $4.66M | $2.84M | $5.99M | $1.25M | $1.93M | $202,000 |
| Free cash flow | -$68.65M | -$70.64M | -$70.66M | -$57.09M | -$56.72M | -$56.48M | -$46.60M | -$39.63M |
| Investing cash flow | -$3.03M | -$3.37M | -$4.66M | -$2.84M | -$5.99M | -$1.11M | -$1.93M | -$202,000 |
| Financing cash flow | $624,000 | $2.58M | $294,000 | $449.38M | $10.36M | $97.81M | $4.18M | $4.51M |
| Depreciation & amortization | $2.43M | $1.85M | $1.28M | $1.25M | $1.07M | $1.03M | $981,000 | $951,000 |
| Stock-based compensation | $15.07M | $14.65M | $15.58M | $11.36M | $11.69M | $9.68M | $10.46M | $7.20M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.